Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the latest kidney cancer clinical updates from ASCO 2025 in this 26-minute medical education video presented by the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. Discover key findings from major clinical trials including KEYNOTE 564's demonstration of adjuvant pembrolizumab maintaining disease-free survival and overall survival benefits for high-risk resected clear cell renal cell carcinoma patients. Explore the impressive long-term follow-up data from CHECKMATE214 showing that after over 9 years, patients with intermediate/poor risk clear cell renal cell carcinoma treated with ipilimumab/nivolumab achieved a median overall survival of 46 months with 30% of patients still alive, 25% progression-free, and 50% maintaining responses, while favorable risk patients demonstrated even better outcomes with a median overall survival of 77 months. Examine the promising results from the ARC20 study evaluating casdatifan (HIF2 inhibitor) combined with cabozantinib, which showed a 46% overall response rate with manageable toxicity profile including grade 3-4 anemia in 24% of patients, hypoxia in 7%, and a low discontinuation rate of 8%. Gain essential insights into these breakthrough developments that are shaping the current landscape of kidney cancer treatment and their implications for clinical practice.
